Dupilumab as a therapy option for treatment refractory mogamulizumab-associated rash
Nicholas A. Trum, Jasmine Zain, Chelsea Abad, Steven T. Rosen, Christiane Querfeld
Abstract
Mogamulizumab has recently been approved for treatment of relapsed/refractory cutaneous T-cell lymphoma (CTCL) in the United States. While not usually life-threatening, successful treatment of its most common adverse effect (mogamulizumab-associated rash, or ‘eruption’) has not been reported outside of the use of topical corticosteroids.1,2 We report a case of treatment refractory mogamulizumab-associated rash that responded positively to dupilumab in a patient with CD8+ poikilodermatous mycosis fungoides.
Topics & Concepts
MedicineRashDermatologyMycosis fungoidesRefractory (planetary science)DupilumabAdverse effectLymphomaInternal medicineAtopic dermatitisAstrobiologyPhysicsCutaneous lymphoproliferative disorders researchT-cell and Retrovirus StudiesFungal Infections and Studies